For people with kidney failure, treatment must take over some of the work healthy kidneys normally perform, including removing waste and excess fluid from the blood. Researchers at the University of California, San Francisco, and Vanderbilt University are pursuing a bioartificial kidney designed to provide that support from inside the body. Their project explores whether engineered components could perform key kidney functions in an implantable device, potentially reducing reliance on treatment delivered repeatedly outside the body. The approach is intended to offer more continuous support, but it remains a subject of research rather than a treatment patients can currently receive.

Today’s main options have important limits. Dialysis filters waste and extra fluid from the blood, but it generally must be repeated on a demanding schedule and can affect daily routines, work, and travel. It also does not reproduce every function of natural kidneys, such as the full range of hormonal and regulatory activity. A kidney transplant can restore more kidney function, yet suitable donor organs are limited, and not everyone is eligible for surgery. Recipients usually need lifelong anti-rejection medicines, which help protect the transplanted organ but can bring side effects and require ongoing monitoring.

The UCSF–Vanderbilt effort aims to investigate an alternative: a device implanted within the body that could combine filtration with biological processes to help manage blood chemistry. In principle, continuous operation could avoid some of the interruptions associated with scheduled dialysis, while an implant might not depend on a donor organ in the same way as transplantation. Those possibilities are goals, not established outcomes. Researchers must demonstrate that the device can function safely and reliably, and that it provides meaningful benefits compared with existing care. The project is experimental, and its safety, effectiveness, durability, and impact on patients remain to be established in people. For now, it represents a promising research direction, not an available or proven replacement for dialysis or transplantation.

The proposed device combines two components because filtering blood is only part of the kidney’s work. Its first stage is a silicon nanopore filter: a precisely engineered membrane with pores intended to let water and selected small waste molecules pass while retaining blood cells and larger, valuable components. Rather than relying on an external pump, the design aims to use the patient’s own blood pressure to drive filtration. This could reduce the need for bulky pumping equipment, although blood flow and pressure would need to remain within safe, effective ranges for the filter to operate reliably.

Filtration alone cannot distinguish every substance the body should remove from those it needs to keep. The second stage, a bioreactor, contains living human kidney cells and is designed to process the fluid emerging from the filter. These cells may reabsorb water and useful nutrients, such as glucose and salts, helping return them to the body rather than allowing them to be lost in the filtrate. They may also carry out other kidney-like activities, including producing or modifying molecules involved in regulating the body’s internal balance. The cells therefore add biological selectivity and activity that a passive membrane cannot provide.

The rationale for pairing engineered filtration with living cells is to divide a complex task between materials and biology. Silicon can provide a compact, controlled barrier for separating components according to size, while kidney cells can respond to the filtered fluid and perform processes that depend on cellular function. In principle, this combination could more closely resemble the coordinated work of a natural kidney than either component could alone. However, the concept remains a developing technology. A prototype should not be understood as reproducing every kidney function: a healthy kidney also regulates electrolytes, acid–base balance, blood pressure, and hormone production through interconnected processes. Demonstrating durable cell survival, safe integration, reliable filtration, and appropriate regulation will be essential before such an implant could serve as a practical alternative to existing treatments.

A 2023 study published in Nature Communications examined whether human kidney cells could remain alive and perform kidney-like functions when housed in an implantable device inside pigs. During the approximately one-week observation period, the cells survived and displayed functions associated with kidney tissue. Researchers also reported no evidence of an immune attack against the cells during that time. These findings offer an early preclinical proof of concept: kidney cells can be maintained in a living animal while separated from its tissues by a specially designed device.

The result matters because keeping cells functional in the body is a central challenge for bioartificial organs. Cells must receive nutrients and exchange substances with the surrounding environment while remaining protected from immune defenses that might destroy them. The study suggests that the device’s membrane can support this balance, at least over a short period in pigs. It therefore provides a basis for further investigation into whether implanted cells could eventually contribute to kidney-related functions, rather than serving only in laboratory systems.

The evidence is limited, however. A brief animal study cannot establish whether the device will be safe, effective, or durable over months or years, nor can it predict outcomes in people. The work was preclinical; the device has not thereby been shown to work in clinical testing or to treat patients. The observation that no immune attack was detected over about a week should not be interpreted as proof of lasting immune protection.

The proposed protection strategy uses nanopores – tiny openings in the device membrane—designed to allow selected substances to pass while excluding immune cells. In principle, this separation could reduce the need for anti-rejection drugs, which can carry significant risks. That possibility remains unproven in patients, and further research must test how reliably the membrane protects cells over longer periods, whether it remains functional in the body, and how the implant performs across relevant safety and effectiveness measures.

Moving a bioartificial kidney from prototype to treatment requires solving a linked set of engineering and biological problems. The UCSF Kidney Project’s approach combines a filtering component with living kidney cells, so success depends not only on separating waste from blood but also on keeping each component effective in the body. A 2026 review in Artificial Organs highlights persistent questions around blood compatibility, device integration, and long-term function. In particular, clot formation on or within the device must be prevented without obstructing filtration or exposing patients to unacceptable risks from measures used to limit clotting.

The living cells present a separate challenge. They require a dependable supply of oxygen and nutrients, and must continue performing their intended functions over periods far longer than short laboratory or animal studies can establish. Researchers need to determine how cells respond to changing blood flow, immune and inflammatory signals, and the mechanical conditions inside an implant. At the same time, the device must connect safely to circulation, avoid damaging blood cells or surrounding tissue, and deliver consistent performance despite variation in a patient’s physiology. A system that works under controlled conditions may behave differently after months or years in a living body.

Further preclinical research is therefore essential to assess durability, safety, and predictable operation before human testing. This includes testing in appropriate animal models, refining how devices are manufactured and quality-controlled, and developing reliable methods for implantation and monitoring. These steps must establish that the implant can be produced consistently and placed without undue surgical risk, while also identifying how failures or complications would be detected and managed. Eventual human trials would then need to evaluate both safety and meaningful benefit, including whether continuous support improves outcomes compared with existing care. The design offers a distinctive route toward kidney support that could operate continuously within the body. However, promising prototypes do not yet establish long-term clinical effectiveness. Substantial research, careful testing, and staged evaluation remain necessary before its real-world potential can be judged.